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Summary 
Injection of anti-CD3 antibodies causes prompt expression of interleukin (IL)-4, IL-2, and inter- 
feron 3' (IFN-3') mRNA among spleen cells. The optimal dose of anti-CD3 for such induction 
was 1.33/~g/animal; lymphokine mRNA was first observed at 30 min, peaked at 90 min, and 
was undetectable (for IL-4) or had declined markedly by 4 h. Cells harvested from spleens of 
mice injected with anti-CD3 90 min earlier  secreted IL-4, IL-2,  and IFN-3' without further 
stimulation. By contrast, in vitro stimulation with anti-CD3 of spleen cell suspensions or splenic 
fragments from noninjected donors failed to cause prompt production of IL-4 and, even after 
24 h of stimulation, the amount of IL-4 produced in such cells was substantially less than that 
secreted within 1 h by spleen cell suspensions or splenic fragments from mice injected with anti- 
CD3 90 min earlier. Production of IL-4 by spleen cells from anti-CD3-injected mice was not 
inhibited by pretreatment with anti-IL-4 antibody or with IFN-3' or tumor growth factor 3 
nor enhanced by treatment with IL-4.  By contrast, CTLA-4 immunoglobulin (Ig) treatment 
clearly diminished IL-4 production in response to in vivo anti-CD3, indicating that cellular 
interactions involving CD28 (or related molecules) were important in stimulation. Cell sorting 
analysis indicated that the cells that produced IL-4 in response to in vivo injection of anti-CD3 
were highly enriched in CD4ros cells with the phenotype leukocyte cell adhesion molecule-1 
(LECAM-1) du~, CD44bns  ht, CD45RB  a~,  NKI.lP  ~  Indeed, the small population of CD4v% 
NKl.lros cells had the great majority of the IL-4-producing activity of this population. Injection 
with Staphylococcal enterotoxin B also caused prompt induction of IL-4 mRNA; the cells that 
were principally responsible for production also had the phenotype of CD4P% NKI.lP  ~  These 
results  suggest that possibility that this rare population of T cells may be capable of secreting 
IL-4 at the outset of immune responses and thus may act to regulate the pattern of priming 
of naive T cells, by providing a source of IL-4 to favor the development of T cell helper 2-like 
IL-4-producing cells. 
I 
mmune responses of CD4  p~ T cells are often dominated 
. by the production of IFN-3~ or of IL-4. Indeed, the choice 
of lymphokine produced by CD4ros T ceils may have a pro- 
found effect on the protective value of that response (1-3). 
Recent in vitro studies have analyzed the factors that deter- 
mine whether naive CD4P  ~  T cells develop into IFN-'y or 
IL-4 producers (4-8).  These studies have revealed a domi- 
nant role for IL-4 itself. Thus, priming T cells in the pres- 
ence of IL-4 leads to the appearance of cells that produce large 
amounts of IL-4 upon rechallenge but little or no IFN-3' (6, 
7). By contrast, priming cells in the presence of anti-IL-4 
antibody results in primed cell populations that produce little 
or no IL-4 but are good IFN-3' producers. For IL-4 to have 
a major effect on priming for IL-4 production, it must be 
present early in the culture. 
IL-4 also has a major effect on in vivo priming of CD4P  ~ 
T  cells to become IL-4-producing cells (9-12).  Treatment 
of mice with anti-lL-4 at the time of priming with hemocyanin 
diminishes the frequency of T cells that produce IL-4 in re- 
sponse to in vitro challenge with hemocyanin (11). Similarly, 
treatment of BALB/c mice with anti-IL-4 at the time of in- 
fection with Leishmania major (9) or Candida albicans (10) en- 
hances their production of IFN-3' and suppresses priming for 
IL-4 production in response to specific challenge,  but only 
if anti-IL-4 is injected very early in the course of the infec- 
tion. Treating C57BL/6 mice with IL-4 at the time of infec- 
tion with L. major increases the appearance of T  cells that 
produce IL-4 upon subsequent in vitro challenge with leish- 
manial antigens (12). CD4r~, T cells from mice in which the 
IL-4 gene has been disrupted by gene targeting produce sub- 
stantially less IL-5 as a result of infection with Nippostron- 
gylus brasiliensis (13). Since IL-5 and IL-4 are both products 
of Th2-type T cell clones (14) and their production by normal 
T cells is often coregulated (5), these results further support 
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sition of the lymphokine-producing phenotype. Taken to- 
gether, these studies indicate that IL-4 produced early in an 
immune response is important in determining the pathway 
of differentiation of naive CD4P  ~ T  cells. 
The central role played by IL-4 in in vivo priming leads 
us to ask what the source of IL-4 might be for determining 
that naive CD4vo, T cells will develop into IL-4 producers. 
Although T  cells themselves are an obvious possibility, the 
very modest production of IL-4 by T cell populations from 
naive donors when stimulated in vitro has cast some doubt 
on their potential importance and raised the possibility that 
other cell types, such as basophils and/or mast cells, might 
be the source of such IL-4 (15-18).  Nonetheless, both Scott 
et al. (19) and Flamand et al. (20) have observed that intrave- 
nous injection of soluble anti-CD3 antibody results in rapid 
but transient expression  of IL-4 mKNA and protein in the 
spleen. In this report, we confirm this observation and show 
that IL-4 protein is induced as early as 30 min after the injec- 
tion of anti-CD3 antibody. It is interesting to note that in 
vitro treatment of spleen cells with anti-CD3 in either sus- 
pension or fragment cultured led to induction of modest 
amounts of IL-4 protein with much slower kinetics indicating 
that in vivo and in vitro regulation of IL-4 production may 
be quite different. 
We show that the cells responsible for IL-4 production 
in response  to intravenous anti-CD3 are largely CD4vo, T 
cells. The CD4p  ~ T  cells that produce IL-4 in response  to 
intravenous injection of anti-CD3 are leukocyte cell adhe- 
sion molecule (LECAM)t-la~,CD44b'igh',CD45RBauL IL- 
4-producing cells are enriched among CD4v", NKI.I~ cells 
suggesting that the major producers are the small popula- 
tion of CD4P  ~  NKI.lP  ~ T  cells that have been previously 
implicated as important lymphokine-producing cells in the 
thymus and bone marrow (21). The production of IL-4 by 
this cell population is independent of the need for IL-4 since 
anti-IL-4 treatment does not inhibit it. Such production of 
IL-4 is also mediated by intravenous injection of Staphylococcal 
enterotoxin B (SEB) suggesting an in vivo mechanism through 
which superantigens may elicit  a source of IL-4 that could 
influence priming to associated conventional antigens. 
Materials  and Methods 
Animals.  Virns-free C57BL/6 and BALB/c female mice, 8-12 
wk of age, were obtained from the Division of Cancer Treatment, 
National Cancer Institute  (Frederick, MD). 
Culture Medium.  RPMI 1640 (Biofluids,  Inc., l~ockville,  MD) 
supplemented with 10% FCS (Inovar Biologicals, Inc., Gaithers- 
burg, MD), 2-ME (50/~M), c-ghtamine (2 raM), penicillin (100 
U/m1), streptomycin (100 I~g/ml), and sodium pyruvate (1 mM) 
was used as culture medium. 
Recombinant Lymphokines.  Recombinant mouse IL-4 was ob- 
tained from a recombinant baculovirus (AcMNPV.IL,4) prepared 
by Cynthia Watson (Laboratory of Immunology, National Insti- 
tute of Allergy and Infectious Diseases [NIAID], National Insti- 
1 Abbreviations used in  this pa~r: LECAM, leukocyte cell adhesion 
molecule; ILT, reverse transcriptase; SEB, Staphylococcal euterotoxin  B. 
tutes of Health [NIH]). 1 U of IL-4 is equal to "~0.5 pg. Human 
recombinant IL-2 was a gift Cetus Corporation (Emeryville,  CA). 
1 U of Ib2, defined as a "Cetus unit", is equal to 6 IU and to 
'~0.3 ng. Purified mouse IFN-3, and TGF-fl were purchased from 
Genzyme Corporation (Boston, MA). 
Reagents.  Anti-CD3 (2Cll) (22) and control hamster mono- 
donal IgG antibody (HH16) (established  by Carol Kinzer, Labora- 
tory of  Immunology, NIAID, NIH) were purified from tissue cul- 
ture supernatants. Purified rat anti-mouse II.-4 (11Bll) (23) was 
prepared by Verax Corporation (Lebanon, NH). Rat anti-mouse 
Fc'y receptor antibody (2.4G2) (24) was purified by Jane Hu-Li 
(Laboratory  of Immunology,  NIAID, NIH). Rat anti-mouse IFN-3, 
(XMG 1.2) (25), FITC-rat anti-mouse LECAM-1 (MEL-14) (26), 
FITC-rat anti-mouse CD44  (PgP-1) (27), FITC-rat anti-mouse 
CD45RB (16A) (28), FITC-rat anti-mouse B220 (RA3-6B2) (29), 
FITC-rat anti-mouse  bA  d (AMS 32.1) (30), PE-rat anti-mouse 
CD4 (RM 4-5) (31), FITC-rat anti-mouse CD8 (53-6.7) (32), and 
biotinylated anti-mouse NKI.1 (PK 136) (33) were purchased from 
PharMingen (San Diego, CA). SEB was purchased from Sigma 
Chemical  Co. (St. Louis,  MO). A soluble  IGC3,1  chimera  of  CTLA-4 
(CTLA-4Ig) (34) and its control human-mouse chimeric  mAb (Chi- 
L6) (35) were provided  by Dr. Peter  S. Linsley  (Bristol-Myers  Squibb 
Pharmaceutical Research Institute,  Seattle, WA). 
In Vivo Treatment  of  Mic~  Mice  were injected  intravenously  with 
a single dose of  anti-CD3 (0.44-12/zg), or SEB (25-800/zg). Con- 
trol mice were injected  with same amount of  hamster IgG or HBSS. 
Spleens were removed  at the specified  times after injection for RNA 
extraction and cell  culture. For some experiments, mice were treated 
with lymphokines, anti-IL-4 or CTLA-4Ig before injection with 
anti-CD3. For the stimulation of Popliteal lymph node cells, 10 
/~g of anti-CD3 in 50/~1 of I-IBSS was injected into both hind foot 
pads of C57BL/6 mice. The draining Popliteal lymph nodes were 
removed for RNA extraction at various times after injection. 
Cell Preparation.  Spleens were removed at various times after 
injection with anti-CD3 or SEB. Cell suspensions were washed 
twice  with  HBSS. Except where  indicated,  5  x  106  spleen 
cells/well  were cultured in 24-well  plates with or without 3/~g/ml 
of anti-CD3 for 1-24 h and supematants harvested  to measure  lym- 
phokine content. In some experiments, spleens  from mice injected 
with or without anti-CD3 were cut into cubes with a volume of 
,~1 mm  3. Individual cubes were placed in wells of 96-well plates 
and cultured with or without anti-CD3 for 1-24 h. 
For the preparation of CD4r' splenic T cells, cells were sus- 
pended at a concentration of 2  x  107/ml in RPMI 1640 con- 
taining 5 mM EDTA (NIH Media Unit) and 5% fetal FCS. The 
cell suspension was incubated with 10/~g/ml each of FITC anti- 
B220; FITC anti-I-A  a, and FITC anti-CD8 antibodies for 30 rain 
at 4"C on a turning wheel. The cells were then washed twice and 
resuspended with magnetic beads coated with sheep anti-FITC an- 
tibodies (Advanced  Magnetics Inc., Cambridge, MA). Cells that 
had bound antibodies were depleted by two rounds of exposure 
to magnetic  field. The residual  cells  were collected  and washed  twice. 
Fluorescence Analysis and Cell Soning.  Fluorescence  staining was 
performed at 4~  in 100/zl containing 1@ CD4-enriched spleen 
cells and PE anti-CD4 in combination with FITC anti-LECAM-1, 
FITC anti-CD44, or FITC anti-CD45RB in PBS containing 3% 
FCS and 0.5% NAN3. For detection of NKI.lr~ cells, biotinylated 
anti-NKl.1 and FITC-labeled  avidin were used. Fluorescence  anal- 
)'sis was carried out with a FACScan  |  Flow Cytometer (Becton 
Dickinson & Co., Mountain View, CA). For sorting experiments, 
a FACStar  |  Plus Flow Cytometer (Becton Dickinson & Co.) was 
used. Cells were maintained at 40C during the sorting process. 
Lymphokine Assays.  CT.4S, an ID4-dependent cell line, and 
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and 11.2 content,  respectively, using serial dilutions of superna- 
tants and comparing responses to those didted by known amounts 
of murine I1.4 and human ID2 as standards. IFN-'y was assayed 
with a specific two-site ELISA (37, 38), with reference standard 
curves prepared using known amounts of rlFN-% 
Analysis of Expression of 11,4, IFN~, and 11,2 mRNA.  Total 
spleen RNA was prepared using the Guanidinium Method (39). 
In brief, after making spleen cell suspensions, cells were washed 
in ice-cold PBS and lysed in 4 ml lysis solution, containing 4 M 
guanidine~thiocyanate  (Fluka Chemika-BioChemik~,  Ronkonkoma, 
NY), 25 mM sodium citrate (pH 7.0), 0.5% N-huroyl sarcosine 
(Sigma Chemical Co.), and 100 mM 2-ME. Lysates  were vortexed 
and stored  at -70~  until further processing. After thawing, 400 #1 
of  2 M sodium acetate (pH 4.0), 4.4. ml of  water-saturated phenol 
(AMRESCO, Solon, OH), and 800 #1 of chloroform-iso-amyl  al- 
cohol (49:1) were added to the lysates with thorough vortexing 
after each addition. The mixture was then chilled on ice for 15 
min and spun at 10,000 g for 15 rain at 4~  The aqueous phase 
was recovered and RNA was precipitated with an equal volume 
of 2-propanol at  -20~  for at least 1 h. The precipitated RNA 
was resuspended  with 600/zl of  lysis solution and an equal volume 
of 2-propanol, and precipitated  at -20~  for I h. Precipitates  were 
pelleted at 4~  washed twice in 70% ethanol, and repelleted at 
4~  at 10,000  g for 20 min. Vacuum-dried  pellets were resuspended 
in  50/zl  of diethylpyrocarbonate-treated double-distilled water 
(DEPC-ddH20) and total RNA concentration was measured. As 
positive controls, mRNAs extracted from the I1.4-producing cell 
line, LT-1 (40) and from purified T cells stimulated with APC plus 
anti-CD3 and anti-I1"4 for 24 h (8) were used. 
For RNA preparation from sorted cells, we used the modified 
method of Chomczynski and Sacchi (39) and resuspended pellets 
in 10-20/zl  DEPC-ddH20. 
For Northern hybridization, 10/zg of RNA from each sample 
were separated by electrophoresis in a 1% agarose/formaldehyde 
gel and blotted onto a nitrocellulose-Nytran  membrane (Schleicher 
and Scliuell, Inc., K~ne, NH). cDNA probes specific for mouse 
I1.4, IFN~ and I1.2 (a 373 EcoRI/HindlII fragment for I1.4; a 
643 bp Pst-1 fragment for IFN-'y; and a 600 bp Pst-1 fragment 
for I1.2) were 32P-labeled by the  random primer method to  a 
specific activity of 5  x  108-2 x  109 cpm/#g. After baking, the 
filters were prehybridized  at 42~  for 1 h and then hybridized  with 
labeled probe for 18 h. The filters were washed twice with 2  x 
SSC and 0.1% SDS at room temperature and twice at 60~  with 
0.1  x  SSC and 0.1% SDS. 
For analysis  of  expression  ofi1.4, IFN-% and I1.2 mRNA from 
sorted cells and  in  other  selected experiments, mRNAs  were 
amplified by a modified standard reverse transcription (RT)-PCR 
amplification  procedure (41). Primers specific  for murine I1.4, I1.2, 
IFN-% and B-actin were prepared by Cynthia Watson. Primer se- 
quences were as follows:  IL4: 5' primer, GAATGTACCAGCAGC- 
CATATC, and 3' primer, CTCAGTACTACGAGTAATCCA;  Ib2: 
5'  primer, ACTTCAAGCTCCACTTCAAGC,  and  3'  primer, 
GCTTTGAGAAAGGGCTATCCA;  IFNw: 5' primer, AACGCT- 
TACACACTGCATCTTGG,  and 3' primer, GACTTCAAAGAG- 
TCTGAGG; ~-actin:  5'  primer, GATGACGATATCGCTGCG- 
CTG, and 3' primer, GTACGACCAGAGGCATACAGG.  Initially, 
2/zl (1/zg) RNA were added to 18/zl of reverse transcription mix- 
ture containing 5 mM MgClz, lx  PCR.  buffer II, 1 mM of each 
dNTP (all from Perkin-Elmer Cetus, Norwalk, CT), 2,000 U/ml 
RNase inhibitor (Promega, Madison, WI), 2.5 U/ml Moloney  mu- 
rine leukemia virus reverse transcriptase (GIBCO BRL, Gaithers- 
burg, MD),  and 0.75 #M specific 3' oligo primer for each lym- 
phokine. Tubes were then placed  in a thermal cycler  (GenAmp  PCR 
System 9600; Perkin-Elmer Cetus) and incubated for 60 min at 
37~  followed by 5 min at 99~  and then 5 min at 5~ 
After reverse transcription, 80/~1 of the PCR mix were added 
to each tube to give a final concentration of 2.5 U Taq DNA poly- 
mense (IL-rkin-Elmer  Cetus), 0.15/zM 5' primer, 0.15/zM 3' ta'imer, 
2 mM MgClz, and lx  PCR buffer 11/100/zl. cDNAs were am- 
plified for 30 cycles, each composed of 94~  for 15 s, 55~  for 
15 s, and 72~  for 1 min. At the end of 30 cycles, samples were 
stored at 4~  until analyzed. After amplification, PCR products 
were separated  by electrophoresis  in 8% acrylamide  gels and visual- 
ized by UV light illumination after ethidium bromide staining. 
Some PCR products were analyzed by Southern blotting,  using 
the probes described above. 
Results 
Expression of  L~nphokine mRNA In Viva  C57BL/6 mice 
were injected intravenously with purified anti-CD3 (2Cll) 
or control hamster antibody (HH16). Spleens were removed 
at various times after injection for RNA extraction, mRNAs 
for IL-4, IFN-% and IL-2 were measured by Northern anal- 
),sis. After injection with 4/zg of anti-CD3, IL-4 mRNA 
was first detectable at 30 min, reached a higher level at 1 h, 
and was markedly diminished at 4 h. (Fig.  1 A). To deter- 
mine the optimal dose of anti-CD3 for this induction of IL-4 
mRNA, Northern analysis was carried out 1 h after injec- 
tion with varying amounts of anti-CD3;  1.33 #g of anti- 
CD3 per mouse was found to maximally  induce IL4 mRNA 
Figure  1.  Anti-CD3  induces the expression of lymphokine  mRNAs 
in vivo. C57BL/6 mice were injected  with (.4) 4/~g; (B) 0.44-12/zg; 
and (C) 1.33/zg  of  purified  anti-CD3 (2Cll), control  hamster  Ig (HH16), 
or HBSS, and spleens were harvested  at the indicated  time for RNA ex- 
traction. RNA from IL-4-secreting  LT-1 cells (LTRNA) is included  as a 
positive control for IL-4 mRNA. 
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ster mAb did not induce detectable IL-4 mRNA. 
To further examine the critical time for maximal induc- 
tion of IL-4 mRNA, spleens were removed as early as 5 min 
after injection of 1.33 #g of anti-CD3. By Northern anal- 
ysis, IL-4 mKNA was first detected at 30 min, reached its 
highest level at 1.5 h, and declined rapidly thereafter (Fig. 
1 C). IFN-3, and IL-2 mRNAs were also initially expressed 
at 30 rain and, although detectable at 4 h, had diminished 
considerably from their peak at 1.5 h. Based on these experi- 
ments, we used 1.33 #g of  anti-CD3 per mouse and removed 
the spleen  at 1.5 h after injection in the following experiments. 
Production of  Lymphokines by Spleen Cells  from Mice Treated 
with Anti-CD3.  To determine whether the expression oflym- 
phokine mKNAs led to production of lymphokine, 5  x  106 
spleen cells from anti-CD3-injected  mice were cultured for 
1 h without additional stimulus. As shown in Fig. 2, a sub- 
stantial amount of  lymphokine  was present in these superna- 
tants;  the time after in vivo injection  to gain and then to 
lose the capacity to produce each of  the lymphokines in short- 
term culture was the same as that for expression of mRNA 
at the time of harvest from the donor. Spleen cells removed 
1.5 h after in vivo treatment produced maximal amounts of 
IL-4, IFN-% and IL-2. We measured lymphokine secretory 
activity as well as lymphokine mKNA in most of the fol- 
lowing experiments. 
Organ Distribution Of  lL-4 raRNA Expression  from Mice In- 
jected with Anti-CD3.  In contrast to the prompt expression 
of IL-4 mRNA in spleen cells from mice injected intrave- 
nously with anti-CD3,  little or no IL-4 mRNA was detected 
in thymocytes or peripheral blood cells of these mice (Fig. 
3). Bone marrow cells and mesenteric  lymph node cells showed 
modest amounts of  IL-4 mRNA in response to injection with 
anti-CD3, but considerably  less than was found in spleen  cells. 
Analysis of penetration of anti-CD3 into spleen, lymph 
nodes, and thymus was done by staining cells with FITC 
anti-hamster IgG and comparing the frequency of positive 
cells with that obtained by staining cells with anti-CD3 plus 
FITC anti-hamster IgG. Half of splenic T cells were stained 
within 15 min of injection of anti-CD3; neither the fraction 
nor the degree of staining increased for up to 90 min after 
injection (data not shown). By contrast, <10% of  lymph node 
Figure  2.  Production oflymphokines by spleen cells from mice treated 
with anti-CD3. Spleen cells from mice injected previously (as indicated) 
with 1.33 #g of anti-CD3 were cultured in 24-well plates at 5  x  106/ml 
for 1 h without additional stimulation. Culture supematants were har- 
vested and tested for production of IL-4, IFN-',/, and IL-2. 
Figure  3.  Organ distribution of Ib4 mRNA expression from mice in- 
jected with anti-CD3. RNA was ~tracted from spleen cells, bone marrow 
cells, mesenteric lymph node cells, thymocytes, and peripheral blood cells 
at various times after injection  of 1.33 #g of anti-CD3. Popliteal lymph 
node cells we~ removed after injection of 10/~g of anti-CD3 in 50 #1 of 
HBSS into hind foot pads. IL,4 mRNA levels were determined  by RT- 
PCR with Southern blot analysis. 
T  cells and virtually none of the CD3  p~  thymocytes had 
bound anti-CD3 at 90 min after injection. This suggests that 
limited (or absent) IL-4 production in these organs is due 
to poor penetration of injected anti-CD3. 
Interestingly,  popliteal lymph nodes from mice injected 
with anti-CD3 in the footpads displayed considerable IL-4 
mRNA; peak levels were reached within 1.5 h but, in con- 
trast to the spleen cells after intravenous treatment with anti- 
CD3, IL-4 mKNA among popliteal lymph nodes cells re- 
mained elevated for 24 h after footpad injection of  anti-CD3. 
Comparison of 11.,-4 Production by Spleen Cells in Response 
to In  Vivo and In  Vitro Stimulation with Anti-CD3.  Spleen 
ceils from mice treated with anti-CD3 for 1.5 h produce large 
amounts of IL-4 without further in vitro stimulation.  By 
contrast,  spleen cells from uninjected mice produced little 
or no IL-4 without in vitro stimulation and failed to pro- 
duce substantial amounts of IL-4 in response to in vitro ex- 
posure to anti-CD3 until 24 h of culture (Fig. 4 A). Even 
at 24 h, the amount of IL-4 in culture supernatants of cells 
from uninjected donors cultured in vitro with anti-CD3 was 
less than the amounts of IL-4 in 1-h culture supernatants of 
spleen cells from mice injected with anti-CD3 1.5 h earlier 
and cultured without any further stimulant. 
We also cultured splenic fragments from mice injected with 
anti-CD3  1.5 h earlier and from uninjected mice with or 
without additional anti-CD3 in vitro (Fig. 4 B). Fragments 
from the "1.5-h injected" mice produced substantial amounts 
of IL-4 within 1 h without the need for the addition of anti- 
CD3. Although splenic fragments from uninjected mice pro- 
duced detectable amounts of  IL-4 in response to culture with 
anti-CD3 somewhat earlier than was observed in spleen cell 
suspensions from these mice, this production was less in mag- 
nitude and still much delayed in comparison  to the IL-4 
production by splenic  fragments from mice injected with anti- 
CD3 but not further cultured with anti-CD3. These results 
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suggest that IL-4 production in response to injection with 
anti-CD3 is not mimicked by in vitro exposure to anti-CD3 
even when the microenvironment of the interaction is preserved 
by the use of splenic fragments. One possibility that might 
account for the failure of  in vitro anti-CD3 to promptly elicit 
IL-4 production in splenic fragments from uninjected mice 
is that the anti-CD3 might penetrate the fragment relatively 
slowly. To rule out this possibility, we prepared splenic frag- 
ments from mice that had been injected with anti-CD3 15 
rain before sacrifice.  As noted above, anti-CD3 binds to T 
cells by this time in amounts as great as at 1.5 h after injec- 
tion. Nonetheless, these fragments, even when cultured in 
anti-CD3, which should ensure a maintenance of anti-CD3 
concentrations, fail to produce IL-4 in substantial amounts 
until 4 h of culture. These results further support the con- 
cept that the splenic fragment culture does not mimic the 
in vivo interaction of anti-CD3 with T  ceils that leads  to 
prompt production of IL-4. 
Surface Phenotype of Cells That Produce IL-4 in Response to 
Injection of Anti-CD3.  We next wished to determine the 
phenotype of the spleen cells that produce IL-4 after in vivo 
treatment with anti-CD3. We first examined the composi- 
tion of the spleen calls in uninjected mice and in mice in- 
jected with anti-CD3 1.5 h earlier. Fig. 5 shows that among 
the CD4~ T  cells, there is a considerable increase in the fre- 
quency of LECAM-1  a~n cells in the spleens  of anti-CD3- 
injected mice. No differences in the frequency of CD44 bright, 
CD45RB a~u, or NKI.lv~  cells were noted, nor were there 
any obvious differences in the expression of these markers 
on CD4n~  cells  (data not shown). 
Spleen cells from mice injected with anti-CD3 1.5 h ear- 
lier were separated into CD4vo~ and CD8~ populations and 
into a series of subpopulations of CD4vo* cells. Using RT- 
PCR to analyze mRNA expression, IL-4-producing cells were 
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Figure  5.  The  frequency  of CD4~,LECAM-1 d~u  spleen cells is in- 
creased in response to anti-CD3 injection. CD4-enriched spleen T cells 
from uninjected  mice or mice injected with anti-CD3 1.5 h earlier  were 
stained with a mixture  of PE anti-CD4 and FITC anti-LECAM-1, FITC 
anti-CD44, FITC CD45RB or biotinylated  anti-NKl.1 and FITC-avidin. 
The percentages shown represent the proportion of bright and dull 
(I,ECAM-1, CD44, and CD45RB), or positive  and negative  (NKI.1) cells 
among the CD4p  ~ T cells. The frequency  of NKI.I~ cells in the experi- 
ment illustrated here was determined  in the absence of a blocking anti- 
FeyRII/III antibody  (2.4G2). However,  in another  experiment  in which 
unlabeled 2.4G2 was added, there was no difference  in the percent of 
NKI.lP  ~ cells among CD4vol cells in uninjected and injected mice al- 
though the absolute percentages  (4.5 and 4.8) were slightly  lower than 
in the experiment shown here. 
found in the CD4P  ~ but not the CD8P  ~  group (Fig. 6 A). 
In  a  separate experiment,  CD4"es,CD8~'g  cells  from anti- 
CD3-injected mice showed little or no IL-4 mRNA (data 
not shown). Among CD4P  ~ ceUs, the IL-4 producers were 
in the group that were LECAM-1  a~u, CD44 bright, and CD4- 
5RB  a~,  consistent with the expression of an activated or 
memory phenotype (42).  CD8  p~  T  ceils  expressed more 
IFN-7 mRNA  than CD4P  ~  T  cells.  Nonetheless, among 
the CD4P  ~  T cells, those that expressed IFN-'? mRNA had 
the same phenotype as those that expressed IL-4 mRNA. 
IL-2 mRNA was observed in both CD4P  ~  and CD8P  ~ T 
cells. Among the CD4P  ~  T  cells, the dominant phenotype 
of the IL-2 producers was also LECAM-1  d~, CD44bng  ht and 
CD45RB  a~. 
In separate experiments, spleen cells from C57BL/6 donors 
injected 1.5 h earlier with anti-CD3 were sorted in CD4P% 
NKI.lP  ~  and  CD4P%NKI.I~'g populations.  The CD4~, Figure 6.  Expression of lymphokine mRNAs by T cell subsets from 
mice treated with anti-CD3. (A) Spleen cells from C57BL/6 mice injected 
with anti-CD3 1.5 h earlier were separated into CD4p  ~ and CDSP  ~ popo- 
latiom and into a series of subpopulations of CD4~, cells (LECAM-la~av 
b,~ht,CD44a,~t and CD45RB'h~).  During the sorting, spleen cells 
were kept at 4~  to insure stability  of  lymphokine  mRNAs. Isohted mRNA 
was analyzed for expression  of Ib4, IFN~, Ib2, and fl-actin by using 
RT-PCR  as described in Materials and Methods. As positive controls, 
mlLNAs extracted from LT-1 cells and from purified T  cells, stimulated 
with APC, anti-CD3 plus anti-IL-4 in vitro for 24 h were used for II~4 
and IFN-'y/IL-2,  respectively. (B) Spleen cells from C57BL/6 mice injected 
with  anti-CD3  1.5  h  earlier  were  sorted into  CD4P%NKI.lP  ~  and 
CD4~,,NKI.I~,g populations (Exp. I). Spleen cells from C57BL/6 (Exp. 
2) or BALB/c (Exp. 3) mice were sorted into total CD4~' and CD4Fo,, 
NKI.lm populations. A series of threefold  diluted RNA samples were 
analyzed for expression of 1L-4 and fl-actin mRNA with RT-PCR. Where 
known, the amount of RNA samples used is reported in/~g. UNSEP, 
total spleen cells before  sorting. 
NKI.lP  ~  population,  being relatively  infrequent,  yielded 
substantially less mRNA as judged by the RT-PCR ampli- 
fication of actin mRNA. Despite this, II.-4 mRNA in this 
population was much greater than in the CD4P%NKI.1  nes 
population (Fig. 6 B, exp. 1). Although this result illustrates 
that CD4P%NKI.lP  ~ T  cells produce substantial amounts 
of IL-4 mRNA, they do not allow a direct determination 
of the total amounts of IL-4 mRNA in the NKI.lP  ~  and 
NKI.I~'~ portions of the CD4~ cell population since the 
latter are much more numerous than the former. To test the 
magnitude of the contribution of CD4P%NKI.lP  ~  cells to 
the production of IL-4 mRNA by the CD4P  ~  cell popula- 
tion, we sorted C57BL/6 cells into total CD4P  ~  and into 
CD4P%NKI.I~ subpopulafions  and compared the amounts 
of IL-4 mRNA by semiquantitative RT-PCR, using actin 
mRNA as a control. As seen in Fig. 6 B (exp. 2), CD4P% 
NKI.I~~  cells  express  approximately  ninefold  less  IL-4 
mRNA  than  do  total  CD4P  ~  cells;  this  conclusion was 
verified by quantitative densitometric comparison of intensi- 
ties IL-4 and B-actin RT-PCR products (data not shown). 
To control for specificity of staining with NKI.1, we sepa- 
rated BALB/c spleen  cells into CD4P%NKI.lneg  cells and 
total CD4~ cells. Since BALB/c cells do not express NKI.1, 
no difference  in IL4 mRNA between these populations would 
be expected.  Indeed, no difference was observed  (Fig. 6 B, 
exp. 3).  These results  imply that the small population of 
CD4p~  cells produces the great majority of the IL- 
4 mRNA expressed by CD4~ cells from mice injected with 
anti-CD3. The data indicate that IL-4 production in the T 
cell population derives  principally from CD4P%LECAM- 
I d~, CD44b~ht,CD45RBa~U,NKl.1P~  cells. 
IL-4 Is Not Required  for IL-4 Production in Response to Anti- 
CD3 Injection.  As noted in the beginning, IL-4 production 
in vitro requires or is markedly enhanced by the presence of 
IL-4 during priming (6, 7). Furthermore, anti-IL-4 treatment 
of mice at the time of immunization or infection diminishes 
subsequent IL-4 production upon rechallenge (9-11). To de- 
termine whether acute production of IL-4 in response to in- 
jection of anti-CD3 was similarly regulated, mice were treated 
with anti-IL-4 or with IL-4, IL-2, IFN-% or TGF-B begin- 
ning at  16 h  before injection with anti-CD3.  These mice 
showed no change in their expression of IL-4 mRNA in re- 
sponse to injection of anti-CD3 (Fig. 7 A). These results in- 
dicate that the factors that appear to regulate priming of T 
cells to become IL-4 producers do not control the acute produc- 
tion of IL-4 in response to injection of anti-CD3 antibody, 
thus suggesting that such cells could be a source of IL-4 for 
the regulation of priming of naive antigen-specific  T  cells. 
Although production of IL-4 mRNA is not influenced by 
the lymphokines that normally regulate priming of IL-4- 
producing T cells, in vivo anti-CD3 stimulation does depend 
upon the interaction of T  cells with cells expressing acces- 
sory ligands since CTLA-4Ig, which blocks the interaction 
of ligands  for  CD28  and  CTLA-4  with  these  accessory 
receptors (35), substantially diminishes the IL-4 response to 
injection of anti-CD3  (Fig.  7 B). 
IL-4 Production  Can Be Promptly  Induced  by Injection of  SEB. 
The capacity of anti-CD3 to rapidly induce IL-4, IFN-'),, and 
IL-2 production in spleen cells in'cares that a potential source 
for the prompt production of these lymphokines exists that 
could be of importance in the process through which naive 
T cells develop into IL-4 or IFN-qr producers. However, anti- 
CD3 itself is not a physiologic stimulant and the frequency 
of T cells that could respond to conventional antigens is prob- 
ably too low for the production of amounts of lymphokine 
sufficient to influence priming of naive T cells. We consid- 
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CD3 injection  but production is inhibited  by CTLA-4Ig. (A) Mice were 
pretreated intraperitoneally with 9 rag of anti-ID4 (11134) or intravenously 
with 5  x  10  ~ U of Ib4, 1/tg of IL-2, 1/tg of IFN-% or 2/~g of TGF-/~ 
16 h and I h before injection of anti-CD3 or HBS$. (/3) Mice were Inetreated 
with CTLA-4Ig (0, 25, 50, 100/~g/mouse) or control human-mouse  chi- 
meric mAb, Chi-L6 (50/~g/mouse)  intravenously I h before injection of 
anti-CD3. Spleens were removed at 1.5 h after injection of anti-CD3 for 
RNA extraction and Ib4 mRNA was measured by Northern blot analysis. 
ered the possibility that superantigens might function like 
anti-CD3 since a response to these molecules could possibly 
make a substantial contribution to the lymphokine environ- 
ment at the time of  priming. Injection of  SEB into C57BL/6 
mice caused the appearance of IL-4 mRNA in the spleen 
within 1.5 h (Fig. 8 A). 200/~g of SEB caused a peak re- 
sponse; IL-4 mKNA could be detected by RT-PCR in re- 
sponse to 25-50/zg of SEB (Fig. 8 B). The amount of IL-4 
mRNA and of  IL-4 protein was less than in response to anti- 
CD3  and  the  time  course  of expression  was  somewhat 
prolonged, since mRNA and activity could still be detected 
in cells harvested 4 h after injection. However, by 24 h after 
injection, no IL-4 mRNA or activity was observed in spleen 
cells from mice injected with SEB or anti-CD3, suggesting 
that the overall  response might be quite similar. Interestingly, 
T cells from SEB-injected mice required a more prolonged 
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Production of I1--4  by T cells from SEB-injected mice. Five 
million spleen cells from mice injected with 1.33/tg of anti-CD3 (1.5 h 
earlier) or 100 pg of SEB (1.5, 4, 24 h earlier) were cultured in individual 
wells of 24-well plates for I h and 24 h without additional stimulus. Cul- 
ture supernatants  were harvested and tested for production of IL-4. 
period of culture to produce IL-4 than did cells from anti- 
CD3-injected mice; more IL-4 was found in culture super- 
natants at 24 h of culture, without further stimulant, than 
after  1 h of culture (Fig. 9). 
CD4P  ~ T cells from mice injected with SEB were sorted 
into  total  CD4v'*  and  CD4P%NKI.ln's  subpopulations. 
IL-4 mRNA was substantially  diminished in the CD4P% 
NKI.lnn cells in comparison  with the total  CD4P  ~  sub- 
population. Densitometric analysis  of  Southern-blotted PCR 
products indicated a threefold diminution, in comparison with 
total CD4P  ~ cells in one experiment and a failure of CD4P% 
NKl.lneg to produce IL-4 in a second experiment (Fig. 10). 
These results indicate that the cells  producing IL-4 in response 
to anti-CD3 and to SEB were of the same phenotype. 
Discussion 
Primed CD4P  ~  T  cells, both in vitro and in vivo, gener- 
ally exhibit either a Thl- or Th2-1ike phenotype (2, 43-48). 
Recently, the mechanisms by which a particular T  cell lin- 
Figure 8.  In vivo challenge with SEB can stimulate prompt produc- 
tion of IL-4. (A) C57BL/6 mice were challenged intravenously with 1.33 
/~g of anti-CD3 or 100/tg of SEB and spleens were removed for RNA 
extraction at indicated times. (B) C57BL/6 mice were injected with var- 
ious doses of SEB as indicated and sacrificed at 4 h after injection to pre- 
pare total spleen RNA. IL-4  mRNA levels  were analyzed  by RT-PCR with 
Southern  blot analysis. 
Figure  10.  CD4~,NKI.I~ T cells promptly produce IL-4  in response 
to in vivo challenge with SEB. Spleen cells from C57BL/6 mice injected 
with 200/zg of SEB 4 h earlier were sorted into total CD4~ and CD4p% 
NKI.I~ populations. Expressinn of II--4  and/3-actin mRNA was mea- 
sured by RT-PCR with Southern blot analysis.  Two experiments are shown. 
In the tint, 1/~g of RNA prepared from each group was used; in the 
second, 0.33/zg of RNA was used. 
1291  Yoshimoto and Paul cage is steered down the path toward these distinctive pheno- 
types have been clarified both by studies of in vitro priming 
requirements (6-8) and by examining in vivo responses  to 
infectious agents and to conventional antigens (9-12). These 
studies have emphasized the importance of cytokines them- 
selves in the determination of a lymphokine-producing  pheno- 
type. IL-4 has been shown to be critical  for priming cells 
to become IL-4 producers (6, 7) and IL-12 enhances priming 
for IFN-3' production (49,  50).  In addition, IL-2, IFN-% 
and TGF-3 have been shown to have effects on the priming 
process (4,  51-54).  If we limit ourselves to the two lym- 
phokines that have a dominant role, IL-4 and IL-12, a poten- 
tial source of one of these,  IL-12,  available at the time of 
priming and produced under conditions that are appropriate 
for  priming cells  to  become IFN-3~-producers,  has  been 
identified (49, 50). That is, macrophages infected with intra- 
cellular microorganisms or even exposed to heat-killed Listeria 
monocytogenes produce substantial amounts of IL-12 (49, 55). 
Since IFN-% produced by T cells primed in the presence of 
II.-12, enhances the capacity of macrophages to destroy intra- 
cellular pathogens, a logical link between production of the 
inducer and the effect of the product is established. 
For IL-4, the situation is more complex. First, the inducer 
and the product are the same (6, 7). Second, IL-4 is known 
to be made mainly by activated T cells and by FceRI  p~ cells, 
mainly cells with the morphology ofbasophils (17, 18). Nei- 
ther of these cell populations appears ideally suited to be a 
physiologic source of IL-4 that could be used in the priming 
process to drive naive cells to become IL-4 producers. For 
the activated CD4P  ~  T cells to do so would require that the 
inducing antigen could lead to their activation.  Unless the 
inducing antigen had polyclonal stimulating capacities, IL-4 
production in response to it would imply that the response 
was secondary, not primary, and would thus not solve the 
problem of how primary IL-4-dominated responses were in- 
duced. The di~culty about FceRIvo, cells being the principal 
source of IL-4 available at the time of priming is that the 
only established physiologic pathway through which these 
cells are stimulated to produce IL4 is by cross-linkage of FceRI 
or FeyRII/III (16, 17). In both cases, the cross-linkage would 
normally be dependent on antibodies of the IgE or IgG classes. 
Since the production of IgE (56), mouse IsG1 (57), and human 
IgG4 (58) is IL-4 dependent, an FcR-mediated stimulation 
of lymphokine production would appear  to be likely only 
after the production of IL-4 had occurred. It is, of course, 
possible  that  non-FcR-mediated stimulation of basophils 
and/or mast cells stimulates IL-4 production; studies addressing 
this possibility are underway. Nonetheless, these arguments 
have led us to more seriously consider the possibility that 
cell types other than basophils and mast cells might be respon- 
sible for the initial burst of IL-4 production that plays a cen- 
tral role in the priming process. 
We have confirmed the prior observations that spleen cells 
can produce large amounts of IL-4 mRNA in response to 
acute in vivo treatment with anti-CD3 (19, 20). Our studies 
reveal several quite interesting features of this response. First, 
in response to intravenous injection, IL-4 production appears 
to be mainly a property of spleen cells, although popliteal 
lymph nodes do show substantial  IL-4 mRNA in response 
to foot pad injection of anti-CD3. Even more striking is the 
fact that rapid induction of IL-4 mRNA and secretion of 
IL-4 in response to anti-CD3 is not mimicked by in vitro 
exposure of spleen cell suspensions or of spleen cell fragments 
to anti-CD3. Although this might still be explained  by a 
critical microenvironmental requirement for stimulation of 
T cells to produce IL-4 promptly, it is equally consistent with 
the possibility that the cell that is responsible for lymphokine 
production is not in the spleen at the time of injection of 
anti-CD3 but only migrates there after stimulation. How- 
ever, we have cultured blood cells in vitro with anti-CD3 
and did not observe prompt production of IL-4 (data not 
shown) suggesting that homing of CD4p  ~ peripheral blood 
T cells to the spleen after activation does not explain these 
results. For the moment, the difference between in vivo and 
in vitro responses  to anti-CD3 are unexplained. 
Our results implicate an unusual T cell population as the 
major producer of IL-4 in response to in vivo injection with 
anti-CD3. Thus, we observed that CD4vo, T cells were the 
major cell population that expressed IL-4 mRNA in response 
to anti-CD3. Among the CD4P  ~ cells, it was cells that ex- 
pressed low levels of LECAM-1, high levels of CD44, and 
low levels of CD45RB that bad virtually all the IL-4-pro- 
ducing capacity (Hg. 6 A). Although this phenotype is con- 
sistent with the IL-4-producing cell being a recently acti- 
vated T cell (42), the observation that the great majority of 
IL-4 was made by the relatively small number of NKI.lp  ~ 
cells in that population, suggests that prompt IL-4 produc- 
tion in vivo may be mediated by a specialized cell popula- 
tion. Indeed, cells with this phenotype and related pheno- 
types have already been implicated as the major source of IL-4 
among thymocytes (21, 59, 60). Thymic migrants within the 
spleen retain substantial IL-4-producing activity in response 
to in vitro treatment with anti-CD3, but only for a few days 
(60).  It  has  been  shown  that  a  population  of CD4P  ~ 
NKI.lP  ~ cells is present within the bone marrow (21). Al- 
though we found only modest amounts of IL-4 mRNA in 
bone marrow cells in response to injection of anti-CD3, it 
is possible that these cells only gain high level responsiveness 
in vivo upon redistribution to the periphery. However,  we 
have not excluded the possibility that normal CD4P  ~ T cells 
that become primed for IL-4 production in vivo acquire the 
expression  of NKI.1, just  as  they become LECAM-1 duu, 
CD44v%  and CD45RB  duu. 
The alternative possibilities (i.e., a specialized cell popula- 
tion or a population of recently primed cells) are consistent 
with the observed lack of requirement of IL-4 at the time 
of stimulation for production of IL-4 in response to in vivo 
anti-CD3. Similarly, the finding that the production of IL-4 
in response to anti-CD3 is inhibited by prior treatment of 
mice with CTLA-4Ig (Fig. 7 B) while indicating an impor- 
tant requirement for a costimulatory signal (34),  does not 
distinguish between these two alternatives. It has been reported 
that the CD4p%NKI.IF~ cell population displays a skewed 
expression  of TCR-B chains,  with V38,  V37,  and V32 
1292  Anti-CD3  Causes Prompt In Vivo II:4 Production dominating (61). We are in the process of determim'ng whether 
V~8 is also more highly represented among the IL-4 producing 
cells derived from in vivo challenge with anti-CD3. 
The possibility that the CD4v",NKI.lP ~ cells described 
here make an important  contribution to the production of 
the IL-4 that biases T cell responses to the Th2-1ike pathway 
would depend very greatly on the likelihood that such cells 
could be induced to produce IL-4 in response to natural im- 
munization  with agents that  normally induce IL-4-domi- 
hated responses. We think it unlikely that responses to con- 
ventional T cell epitopes on these immunogens could recruit 
a sufficiently large fraction of the potential IL-4 producers 
to cause the secretion of enough IL-4 to affect a true primary 
response.  However, the finding that SEB can induce a re- 
sponse rather like that mediated by anti-CD3,  although of 
lower magnitude (Figs.  8 and 9), raises the possibility that 
immunogens that have associated superantigens might be able 
to stimulate a sufficient number of CD4~,NKI.lP ~ so that 
the local concentration of IL-4 available at the time of priming 
might be adequate for the differentiation of naive, antigen- 
specific T  cells to develop into IL-4 producers.  This would 
predict that agents such as nematodes and allergens would 
have associated superantigens. 
Despite the many unresolved issues raised by these experi- 
ments, the demonstration of a cell population that promptly 
expresses IL-4 mRNA in vivo in response to receptor-ligation 
provides an important advance in the effort to determine the 
physiologic mechanisms through which immunization leads 
to CD4P  ~  T  cell responses dominated by Thl-like ceils or 
Th2-1ike cells. 
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